On April 26, 2021 InnoCare Pharma reported The 2021 edition of the Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines (hereinafter referred to as the "Guidelines") was released recently (Press release, InnoCare Pharma, APR 26, 2021, View Source [SID1234578432]). InnoCare’s novel BTK inhibitor orelabrutinib was listed as a Level I recommended treatment for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and r/r mantle cell lymphoma (MCL).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition, for r/r diffuse large B-cell lymphoma (DLBCL), the Guidelines recommend that BTK inhibitors be considered to be used in combination with chemotherapy, and specifically mentioned that innovative drugs such as orelabrutinib be recommended for single or combinational therapy for r/r DLBCL based on preliminary efficacy in clinical studies. For primary central nervous system lymphoma (PCNSL), BTK inhibitor orelabrutinib demonstrates good blood-brain barrier penetration. The Guidelines recommend BTK inhibitors to be used in combination with chemotherapy, and specifically pointed out that orelabrutinib is expected to show efficacy in the treatment of PCNSL.
The Guidelines are aimed at further promoting the standardization of lymphoma diagnosis and treatment in China.
Professor Jun Ma, Chairman of the CSCO Board of Supervision and Director of the Harbin Institute of Hematology, said: "Lymphoma is one of the top ten most common tumors in China, and it is also the fastest growing hematological malignant tumor in recent years. The five-year survival rate of lymphoma patients in China still lags behind that of U.S. and Europe. Therefore, it is very important to standardize the diagnosis and treatment. The CSCO Guidelines not only reflect the continuous improvement of drug research and development in China, but also contribute to the standardization of lymphoma diagnosis and treatment, which will benefit patients."
Professor Jun Zhu, Executive Director of the CSCO, Director of the Lymphoma Department of Peking University Cancer Hospital, said: "As the principal investigator of orelabrutinib, I am very pleased that orelabrutinib has been recognized by the experts and recommended by the Guidelines. As a lymphoma physician, we can provide Chinese patients with better anti-tumor drugs, so that our patients can obtain greater benefit. This is what we have been striving for."
"Orelabrutinib was recommended by the CSCO Guidelines four months after its approval, which demonstrates the recognition for orelabrutinib by CSCO experts. With the further improvement of research and development, we believe that our lymphoma diagnosis and treatment can be further refined and standardized to better benefit patients in China." said Dr. Jasmine Cui, co-founder, chairwoman and CEO of InnoCare.
Orelabrutinib is a novel BTK inhibitor with high target selectivity. It was approved for marketing by the National Medical Products Administration (NMPA) of China on December 25, 2020 for the treatment of patients with r/r CLL/SLL and r/r MCL.